{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:37:46Z","timestamp":1767965866589,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173683"],"award-info":[{"award-number":["82173683"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011841","name":"Xinxiang Medical University","doi-asserted-by":"publisher","award":["XYBSKYZZ202185"],"award-info":[{"award-number":["XYBSKYZZ202185"]}],"id":[{"id":"10.13039\/501100011841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejmech.2024.116444","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T15:20:32Z","timestamp":1714144832000},"page":"116444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Discovery of potent and novel dual NAMPT\/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma"],"prefix":"10.1016","volume":"271","author":[{"given":"Chunjia","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuting","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116444_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116444_bib2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrc3340","article-title":"The NAD metabolome-a key determinant of cancer cell biology","volume":"12","author":"Chiarugi","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116444_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.970553","article-title":"Review of various NAMPT inhibitors for the treatment of cancer","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116444_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115607","article-title":"Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery","volume":"258","author":"Tang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115080","article-title":"Fluorescent and theranostic probes for imaging nicotinamide phosphoribosyl transferase (NAMPT)","volume":"248","author":"Sun","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib6","unstructured":"S. Fratta, P. Binieck, A.J. Moreno-Vargas, A.T. Carmona, A. Nahimana, M.A. Duchosal, F. Piacente, S. Bruzzone, I. Caffa, A. Nencioni, I. Robina, Synthesis and Structure-Activity Relationship of New Nicotinamide Phosphoribosyltransferase Inhibitors with Antitumor Activity on Solid and Haematological Cancer."},{"key":"10.1016\/j.ejmech.2024.116444_bib7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/CAD.0b013e3283287c20","article-title":"Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777","volume":"20","author":"Beauparlant","year":"2009","journal-title":"Anti-Cancer Drug."},{"key":"10.1016\/j.ejmech.2024.116444_bib8","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1158\/1535-7163.MCT-16-0197","article-title":"Dual and specific inhibition of NAMPT and PAK4 by KPT-9274 decreases kidney cancer growth","volume":"15","author":"Abu Aboud","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116444_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113022","article-title":"Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer","volume":"211","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116127","article-title":"HDAC\/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells","volume":"266","author":"Yue","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib11","doi-asserted-by":"crossref","first-page":"16694","DOI":"10.1021\/acs.jmedchem.3c01362","article-title":"Discovery of dual function agents that exhibit anticancer activity via catastrophic nicotinamide adenine dinucleotide depletion","volume":"66","author":"Fu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1021\/acs.jmedchem.2c01954","article-title":"Dual nicotinamide phosphoribosyltransferase (NAMPT) and indoleamine 2,3-dioxygenase 1 (Ido1) inhibitors for the treatment of drug-resistant nonsmall-cell lung cancer","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib13","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1021\/acs.jmedchem.2c01990","article-title":"Discovery of highly potent nicotinamide phosphoribosyltransferase degraders for efficient treatment of ovarian cancer","volume":"66","author":"Bi","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bbrc.2009.11.066","article-title":"Nicotinamide phosphoribosyltransferase (NAMPT\/PBEF\/visfatin) is constitutively released from human hepatocytes","volume":"391","author":"Garten","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2024.116444_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091045","article-title":"Resveratrol differentially regulates NAMPT and SIRT1 in Hepatocarcinoma cells and primary human hepatocytes","volume":"9","author":"Schuster","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.116444_bib16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bbrc.2015.01.111","article-title":"FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells","volume":"458","author":"Schuster","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2024.116444_bib17","first-page":"7231","article-title":"FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells","volume":"126","author":"Zhang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2024.116444_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/14737140.2017.1298447","article-title":"Could NAMPT inhibition become a potential treatment option in hepatocellular carcinoma? Expert Rev","volume":"17","author":"Garten","year":"2017","journal-title":"Anticancer Ther."},{"key":"10.1016\/j.ejmech.2024.116444_bib19","article-title":"AZD5153, a bivalent BRD4 inhibitor, suppresses hepatocarcinogenesis by altering BRD4 chromosomal landscape and modulating the transcriptome of HCC cells","volume":"10","author":"Lin","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2024.116444_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.954512","article-title":"Personalized quantitative models of NAD metabolism in hepatocellular carcinoma identify a subgroup with poor prognosis","volume":"12","author":"Chedere","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.116444_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41586-019-1150-2","article-title":"NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodeling","volume":"569","author":"Chowdhry","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116444_bib22","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1158\/0008-5472.CAN-16-3079","article-title":"Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors, and DNA repair","volume":"77","author":"Caffa","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116444_bib23","doi-asserted-by":"crossref","first-page":"13141","DOI":"10.1074\/jbc.R700001200","article-title":"The double bromodomain-containing chromatin adaptor BRD4 and transcriptional regulation","volume":"282","author":"Wu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.humgen.2023.201196","article-title":"Review on: BRD4 inhibitors for anticancer research","volume":"37","author":"Singh","year":"2023","journal-title":"Human Gene."},{"key":"10.1016\/j.ejmech.2024.116444_bib25","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/acs.jmedchem.0c01487","article-title":"Targeting bromodomain and extraterminal proteins for drug discovery: from current progress to technological development","volume":"64","author":"Tang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/acs.jmedchem.3c00996","article-title":"Discovery of novel inhibitors of BRD4 for treating prostate cancer: a comprehensive case study for considering water networks in virtual screening and drug design","volume":"67","author":"Zhong","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib27","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1021\/acs.jmedchem.3c00520","article-title":"Precise conformational control yielding highly potent and exceptionally selective BRD4 degraders with strong antitumor activity","volume":"66","author":"Hu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116009","article-title":"Design and synthesis of dual BRD4\/Src inhibitors for treatment of triple-negative breast cancer","volume":"264","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116052","article-title":"3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia","volume":"265","author":"Ali","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib30","first-page":"57","article-title":"NF-\u03baB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells, Leuk","volume":"74","author":"Hishiki","year":"2018","journal-title":"Res."},{"key":"10.1016\/j.ejmech.2024.116444_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature14898","article-title":"Transcriptional plasticity promotes primary and acquired resistance to BET inhibition","volume":"525","author":"Rathert","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116444_bib32","doi-asserted-by":"crossref","first-page":"14247","DOI":"10.1021\/acs.jmedchem.1c00625","article-title":"Discovery and preclinical pharmacology of an oral bromodomain and extra-terminal (BET) inhibitor using scaffold-hopping and structure-guided drug design","volume":"64","author":"Gavai","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib33","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.18632\/oncotarget.6275","article-title":"Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.116444_bib34","article-title":"BET Inhibitor Suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4 11","volume":"11799","author":"Choi","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116444_bib35","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3389\/fonc.2019.01471","article-title":"Targeting BET proteins with a PROTAC molecule elicits potent anticancer activity in HCC cells","volume":"9","author":"Zhang","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.116444_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/gutjnl-2019-318918","article-title":"Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma","volume":"70","author":"J\u00fchling","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2024.116444_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117152","article-title":"Design, synthesis, and biological evaluation of quinoxalinone derivatives as potent BRD4 inhibitors","volume":"78","author":"Xu","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib38","doi-asserted-by":"crossref","first-page":"10581","DOI":"10.1021\/acs.jmedchem.1c00683","article-title":"Rational multitargeted drug design strategy from the perspective of a medicinal chemist","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib39","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.3390\/molecules25163633","article-title":"Structural basis of beneficial design for effective nicotinamide phosphoribosyltransferase inhibitors","volume":"25","author":"Tanuma","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116444_bib40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nsmb1105","article-title":"Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents","volume":"13","author":"Khan","year":"2006","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2024.116444_bib41","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116444_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.ejmech.2024.116444_bib43","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1021\/acs.jmedchem.6b00324","article-title":"Structure-based design of potent nicotinamide phosphoribosyltransferase inhibitors with promising in vitro and in vivo antitumor activities","volume":"59","author":"Bai","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib44","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1021\/acs.jmedchem.2c01607","article-title":"Design, synthesis, and biological evaluation of a potent dual EZH2\u2212BRD4 inhibitor for the treatment of some solid tumors","volume":"66","author":"Huang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib46","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/wcms.1121","article-title":"An overview of the Amber biomolecular simulation package","volume":"3","author":"Salomon-Ferrer","year":"2013","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116444_bib47","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.1021\/acs.jmedchem.2c00077","article-title":"Discovery of small molecules simultaneously targeting NAD(P)H:Quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase: treatment of drug-resistant non-small-bell lung cancer","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112396","article-title":"Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents","volume":"198","author":"Wu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116444_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114439","article-title":"Dual-functional antitumor conjugates improving the anti-metastasis effect of combretastatin A4 by targeting tubulin polymerization and matrix metalloproteinases","volume":"238","author":"Yang","year":"2022","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424003246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424003246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T09:36:29Z","timestamp":1717234589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424003246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":49,"alternative-id":["S0223523424003246"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116444","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of potent and novel dual NAMPT\/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116444"}}